2016 Round Table
ALGERIA 2020 & Biotechnology: What future & model for Algeria?
The need to communicate a clear vision, a political decision set out with a roadmap and concrete projects in the short, medium and long terms..
The presence of a dedicated interlocutor and decision-maker who would be the vis-à-vis the different actors for the biotechnology project like biopolis in Singapore
The importance of government incentive programs to encourage the private sector to invest, build a real biotechnology industry and encourage research in Algeria.
Audience
- Director General of Pharmacy, MOH, Dr. Hamou Hafed
- Director General of Health, MOH, Pr. Mohamel l’Hadj
- General Manager of PCH, M’hamed Ayad
- Director General of Social Security, Djaouad Bourkaib & Dr. Mohamed Lamine Ghanem
- Director of INSP, Pr. Mokhtar Hasbellaoui
- Senior management of companies & healthcare sector representative : Novo Nordisk, AstraZeneca, Clinica Group, Merck, ANPP, Deloitte, Sevier
- Director Geenral of the Biotechnology Center
Attending Experts
Dr. Siew Hwa ONG
Founder & CEO, Acumen Research Laboratories & Chairman
Dra.C. Mayra Ramos Suzarte
Deepanwita Chattopadhyay
CEO & Chairman IKP Knowledge Park
Miquel Bonachera Sierra
CEO AB Bioticts, for ASEBIO
Contact us
Tour Sebastopol, 3 Quai Kleber, 67000 Strasbourg
+33 - 388 - 23 - 70 - 92
+33 - 643 - 12 - 95 -13
+213 - 549 - 55 - 62 - 05
